Skip to main content

News

Why should rheumatologists discuss exercise in PMR?

My colleague says, “I simply refer to physiotherapy. I don’t have time to discuss exercises, we need that time to discuss medications, side-effects, etc.” I sympathise. How do we promote activity and muscle strength among our patients?

FDA Approves Infliximab Biosimilar for Subcutaneous Use

Another infliximab biosimilar has been FDA approved, but this new version of Inflectra can be given subcutaneously for patients with inflammatory bowel disease.

Subcutaneous Biosimilars? (10.27.2023)

Dr. Jack Cush reviews RheumNow's top entries the PMR Campaign, news, journal reports and regulatory actions.

Anti-Phospholipid Antibodies - Infrequent in Certain Groups

MedPage Today

Among patients with systemic lupus erythematosus (SLE), high titers of anti-phospholipid (aPL) antibodies were most prevalent in whites and Latinos and less so for Black and Asian individuals, researchers found.

TNR - Controversies in PMR

A TNR Panel discussion on controversies in PMR: diagnosis, imaging, PCP roles, Lumping vs. Splitting.

Featuring Drs. Sarah Mackie, Wolfgang Schmidt, and Len Calabrese.

Moderated by Dr. David Liew.

Recorded on 10/24/2023

ACR 2022 Guideline on Glucocorticoid-Induced Osteoporosis

The ACR has published its updated recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP) for patients receiving >3 months treatment with glucocorticoids (GCs) ≥2.5 mg daily.

PMR and Telemedicine: do we really need an office visit?

When we are considering a diagnosis of PMR, it is key to evaluate the patient accurately and efficiently. Can we use a synchronous audiovisual visit or a rheumatology eConsult to evaluate the patient's symptoms quickly? Does it allow us to make an accurate diagnosis? I would argue that for most of these cases we indeed can. 

Methotrexate in OA (10.20.2023)

Dr. Jack Cush discusses the news, journal articles and regulatory actions. This week we discuss JAKne, DLE and SLE and more.

FDA Approves Bimekizumab for Plaque Psoriasis

UCB announced today that the US Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx)) for the treatment of moderate to severe plaque psoriasis in adults who needing systemic therapy or phototherapy.

PMR and Palindromic Rheumatism Similarities

I'd like to discuss the similarities between polymyalgia rheumatica and palindromic rheumatism. And in doing that, highlight how these similarities help us understand the relationship between polymyalgia rheumatica and rheumatoid arthritis. Perhaps not everybody watching this will be very familiar with palindromic rheumatism. It is considered uncommon, but every rheumatologist sees it in their practice.

2023 EULAR Lupus Management Recommendations

EULAR has published updated recommendations for the management of systemic lupus erythematosus (SLE) based on new evidence and expert opinion - formulationg five overarching principles and 13 recommendations.

Could Methotrexate Work in Hand Osteoarthritis?

Lancet reports the results of the METHODS study from Australia where hand osteoarthritis (HOA) patients benefitted from 6 months of methotrexate (MTX) - as long as there was MRI synovitis!

×